Emergency Department Substance Use Surveillance System
Closed Posted
- Opportunity number
- EDS-EDS-24-001
- Agency
-
Office of the National Drug Control Policy
Executive Office of the President
- Applications due
- Award size
- Up to $150,000
Opportunity facts
- Assistance listings
-
- 95.007 Research and Data Analysis
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- 501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- Higher Education Inst. (Public)
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
This Federal Grant Opportunity seeks to further refine and expand a methodology for obtaining drug early warning indicators through broader testing of urine samples collected from emergency department populations across the United States. The Executive Office of the President Office of the National Drug Control Policy is offering this opportunity as a cooperative agreement for public non-profit institutions, including higher education institutions and hospitals. The key objectives are to re-test previously collected urine samples for an expanded panel of drugs, including emerging substances, to determine drug patterns and exposure in different subpopulations and geographies. The project will also involve collecting and analyzing de-identified nationally representative patient electronic health records to provide further context on drug exposure and consequences.
The funding available under this opportunity is intended to support research and data analysis activities, with recent Federal Grant Awards under this program ranging from $100,000 to $3,000,000 for 12-month project periods. The place of performance will be locations throughout the United States, as the goal is to apply this testing methodology and supplementary analysis on a national scale to reinforce best practice guidelines, testing standardization, and build local and national surveillance capacity.
Synopsis
This project seeks to further refine and geographically expand a methodology for obtaining drug early warning indicators through broader testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations - including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. A similar methodology is promising for use in other venues, such as in trauma units and emergency departments, where biological samples are often collected from patients. Before the specimens are discarded, the project will re-test them for an expanded panel of drugs, including xylazine, fentanyl, methamphetamine, and other new psychoactive substances (NPS); to determine what old and new illicit drugs are detected or missed by conventional testing protocols, and how the drug patterns might vary by subpopulation and geography. Bypassing the expense of collecting the original specimens and re-using those that have already been tested with known results yields a relatively inexpensive and timely picture of emerging drugs in a given subpopulation and locality. Hospital and de-identified nationally representative patient electronic health records (EHRs) should be collected and analyzed to put re-tested urine positivity results into a larger regional and national context of drug exposure and consequences. ONDCP is seeking to apply this testing methodology and insight from supplemental EHR investigations to emergency department and other hospital-system populations in locations throughout the United States to reinforce best practice guidelines, testing standardization, and build local and national surveillance capacity.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity